Searched for
PHARMACEUTICAL BUSINESS
India's manufacturing growth slows in Q1 as West Asia conflict weighs: FICCIIndia's manufacturing sector anticipates a slower growth phase in the April-June quarter of FY27, influenced by the West Asia conflict. Whi...- India's manufacturing growth expected to moderate in April-June due to West Asia crisis: FICCIIndian manufacturing growth is set to slow in the first quarter of FY27, with a FICCI survey revealing muted business sentiment. This moder...
- India's underperformance sets stage for recovery, says JM Financial's Deepak GuptaIndian equities are showing signs of a potential rebound, with attractive valuations and improved currency stability, according to Deepak G...
- Manufacturing growth seen moderating in Q1 as West Asia crisis weighs on sentiment: FICCIIndia's manufacturing sector anticipates a slowdown in April-June FY27, influenced by West Asia tensions impacting business confidence. Des...
- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- India Inc's green transition triggers hiring surgeAs organisations step up their sustainability efforts, demand is also growing for senior leadership talent, including business heads for re...
- Twinkle Papers IPO opens for subscription today. Check GMP, price band and other detailsRetail investors can bid for a minimum of 4,000 shares, requiring an investment of Rs 2.76 lakh at the upper end of the price band. Novus C...
- Employers across globe continue to have confidence in MBA graduates despite AI boom: GMAC reportGlobal employers maintain strong faith in MBA graduates, with over half believing business degrees are more crucial than ever as technology...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- Strides Pharma sells majority stake in arm Pivot Path for Rs 100 croreStrides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Shelf-life norms for imported drugs may be relaxed to reduce wastageIndia is set to revise rules for imported medicines, proposing a 12-month minimum residual shelf life instead of the current 60% rule. This...
- Health ministry issues proposal for one-year residual shelf life for imported drugsThe Union Health Ministry is proposing to relax import rules for medicines, requiring a minimum 12-month shelf life upon arrival instead of...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- India, Uzbekistan aim to double bilateral trade in 3 yearsIndia and Uzbekistan are set to significantly boost bilateral trade, aiming to double it within three years. Discussions at the recent Inte...
Load More
